Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Simulations Plus reports Q1 revenue decline, eyes global expansion

Simulations Plus (SLP) navigated Q1 challenges with a focus on innovation, growth, and shareholder value.
Balancing revenue streams and exploring global opportunities position the company for future success.
Commitment to science, R&D, and market expansion underscores strategic vision and adaptability.
Positive outlook for future quarters driven by achievements, market traction, and evolving strategies.

Simulations Plus reports solid Q2 earnings, eyes growth opportunities

Simulations Plus delivered a strong quarter with revenue and net income growth.
The company's focus on collaborations and AI technologies bodes well for future growth.
Challenges in certain software products and economic impacts on sales cycles noted.
Opportunities in agrochemicals, biosimilars, and inorganic growth avenues are being pursued.

Simulations Plus (SLP) reports strong Q3 earnings and expands into oncology with Immunetrics acquisition

Simulations Plus (SLP) delivered a robust performance in Q3 2023, driven by revenue growth, strategic acquisitions, and operational initiatives.
While facing challenges such as renewal rate fluctuations, SLP remains well-positioned to capitalize on opportunities for growth and expansion.
Guidance for fiscal 2023, strong backlog visibility, and the Immunetrics acquisition underscore SLP's positive trajectory and potential for sustained success.

Simulations Plus (SLP) posts strong Q4 results, eyes biosimulation growth

Simulations Plus (SLP) delivered a solid performance in Q4 2023, showcasing revenue growth, strong margins, and notable achievements. While facing challenges from market conditions and nonrenewals, the company is optimistic about growth opportunities in biosimulation and revenue contributions from the Immunetrics acquisition.

Simulations Plus (SLP) reports stellar Q1 results and eyes growth

Simulations Plus (SLP) demonstrated robust performance across key segments, with strong revenue growth and profitability metrics.
While facing challenges like varied client budgets and revenue declines in certain units, the company is well-positioned to capitalize on growth opportunities.
With a focus on customer loyalty, operational efficiency, and strategic investments, Simulations Plus is poised for continued success in the market.

Simulations Plus (SLP) reports strong Q2 growth and outlook

Simulations Plus (SLP) demonstrated robust growth in Q2 2024
Strong performance in both Software and Services segments
Positive market outlook and strategic positioning for future growth
Focused on meeting fiscal 2024 guidance targets

Simulations Plus Reports Strong Q3, Eyes Growth Initiatives

Simulations Plus delivered a strong performance in Q3 2024, driven by growth in both software and services. The launch of new software and the acquisition of Pro-ficiency highlight strategic moves to enhance offerings and market position. However, challenges in gross margin and client spending patterns could impact future performance. Overall, the company remains focused on growth and operational integration.

Simulations Plus beats earnings expectations, eyes TAM expansion opportunities

Simulations Plus delivered strong financial results, exceeding revenue and EPS expectations. While facing challenges in meeting organic growth targets, the company's strategic investments and acquisitions position it well for future growth. With a focus on expanding TAM and maintaining profitability, Simulations Plus remains optimistic about its prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will participate in the 16th Annual Needham Virtual Technology & Media Conference on Thursday, May 20, 2021.

Simulations Plus to Present at 16th Annual Needham Virtual Technology & Media Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus (SLP) announced today that its securities will be listed on The Nasdaq Global Select Market with the open of business on May 13, 2021

Simulations Plus Uplisted to The Nasdaq Global Select Market®

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus releases ADMET Predictor APX.2, its flagship machine learning platform with new & enhanced capabilities in discovery PBPK simulations

Simulations Plus Releases ADMET Predictor® (X.2)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that the US FDA renewed its licensing to the DILIsym Services division's flagship QST software platform, DILIsym.

U.S. FDA Renews Licenses of DILIsym Software

Simulations Plus's total return overperformed the Dow average for my 64 month test period by 471.60%, which is fantastic. Simulations Plus three-year past CAGR of 19% is well above average and will give you great growth with the increasing need for testing new drugs faster than before.

Simulations Plus: Growth Speculation In The Drug Industry

Simulations Plus' (SLP) fiscal second-quarter results benefit from strong performance of the company's higher-margin software business.

Simulations Plus (SLP) Q2 Earnings & Revenues Top Estimates

Simulations Plus, Inc.'s (SLP) CEO Shawn O'Connor on Q2 2021 Results - Earnings Call Transcript

Shares of Simulations Plus (NASDAQ:SLP) moved higher after the company reported Q2 results. Quarterly Results Earnings per share increased 25.00% over the past year to $0.15, which beat the estimate of $0.14.

Simulations Plus: Q2 Earnings Insights

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported record 2nd quarter results for FY2021. Net revenue of $13.1 million, up 27% over 2QFY20; YTD revenue of $23.8 million.

Simulations Plus Reports Record Second Quarter Fiscal 2021 Financial Results

On Monday, April 12, Simulations Plus (NASDAQ:SLP) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

Simulations Plus's Earnings: A Preview

Simulations Plus (SLP) fiscal second-quarter results are likely to reflect gains from solid uptick in modeling and simulations workflow platform for drug development across pharma and biotech industries.

Simulations Plus (SLP) to Post Q2 Earnings: What to Expect?

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports excellent results from its Artificial Intelligence-driven Drug Design (AIDD) module in ADMET Predictor in testing by partner.

Simulations Plus Reports Successful Results from AIDD Collaboration with Large Pharmaceutical Company

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its 2nd quarter fiscal year 2021 results on Monday, April 12, 2021, with a webcast at 4:15 pm ET.

Simulations Plus Sets Date for Second Quarter Fiscal Year 2021 Earnings Release and Conference Call

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the formation of a Scientific Advisory Board to guide the development of its RENAsym QST kidney injury software platform.

Simulations Plus Forms Scientific Advisory Board for RENAsym Consortium

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the successful launch of its 2021 MIDD+ Scientific Conference with speakers from industry, academia, & regulatory agencies.

Simulations Plus Hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will present at Oppenheimer's 31st Annual Healthcare Conference on March 16, 2021, beginning at 2:30 p.m. ET.

Simulations Plus to Present at Oppenheimer Healthcare Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that its DILIsym division and the University of Pittsburgh Drug Discovery Institute jointly received a Phase I SBIR grant.

Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration

AbbVie

Premier

What's better than rapid growth and a dividend payment?

3 Top Healthcare Stocks That Can Make You Richer in 2021 (and Beyond)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host fireside chat at BTIG's Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb. 18, at 12pm ET.

Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the release of GastroPlus 9.8.1 with key enhancements to improve efficiency and inform regulatory decision making.

Simulations Plus Releases GastroPlus® Version 9.8.1

The modelling and simulation software market for drug discovery and development is niche and IP-intensive, with high barriers to entry. Simulations Plus has a good track record and strong balance sheet, providing opportunities for multiple pathways to growth.

Simulations Plus: Niche Market Leader With Strong Balance Sheet

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced an agreement to distribute Lixoft's MonolixSuite in China with Mosim, one of China's leading clinical CROs.

Simulations Plus Enters Agreement with Distributor in China

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it is partnering with the Institute of Pharmaceutical Sciences (ICF) in Brazil, to expand into South America.

Simulations Plus Expands Marketing and Sales Operations in South America Through Partnership with the Institute of Pharmaceutical Sciences

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it has awarded a grant to Uganda's Makerere University funding upgraded infrastructure to facilitate research.

Simulations Plus Awards Infrastructure Improvement Grant to Makerere University Department of Pharmacology and Therapeutics

Simulations Plus (SLP) fiscal first-quarter results reflect solid software and service revenue growth. However, coronavirus crisis affected renewals.

News for Simulations Plus Stock (SLP)